Visiongain Report Looks at Opportunities Within the $6.3bn Anti-Obesity Drugs Market
LONDON, December 5, 2018
LONDON, December 5, 2018 /PRNewswire/ --
Global Anti-Obesity Drugs Market Forecast 2018-2028
Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs
The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 119 tables and 139 figures- all unavailable elsewhere.
The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
• Global Anti-obesity Drugs Market forecast from 2018-2028
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:
• Generic Drugs
• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:
• Prescription Drugs
• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:
• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs
• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
• GlaxoSmithKline (GSK)
• Novo Nordisk
• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
• This report gives an overview of pricing and reimbursement in the US and EU.
• This report provides a SWOT Analysis of the global anti-obesity drugs market.
Visiongain's study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2018-2028/
Did you know that we also offer a report add-on service? Email email@example.com to discuss any customized research needs you may have.
American Medical Association
KT&G Life Sciences
Shionogi & Co., Ltd
World Health Organization (WHO)
To see a report overview please e-mail Sara Peerun on firstname.lastname@example.org